Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will release its first quarter 2024 financial results on Tuesday, May 7, 2024, at 8:00 a.m. ET. Management will host a conference call on the same day at 8:30 a.m. ET.

https://mma.prnewswire.com/media/607886/Curis_Logo.jpg

To access the live conference call, please dial (800)-836-8184 fromthe United Statesor (646)-357-8785 from other locations, shortly before8:30 a.m. ET. The conference call can also be accessed on the Curis website atwww.curis.comin the 'Investors' section. A replay of the conference call will be available on the Curis website shortly after completion of the call.

About Curis, Inc.

Curis is a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor. Emavusertib is currently undergoing testing in the Phase 1/2 TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase 1/2 TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS), both of which have received Orphan Drug Designation from the U.S. Food and Drug Administration. Emavusertib is also being evaluated as a frontline combination therapy with azacitidine and venetoclax in patents with AML. Curis, through its 2015 collaboration with Aurigene, has the exclusive license to emavusertib (CA-4948). Curis licensed its rights to Erivedge(R) to Genentech, a member of the Roche Group, under which they are commercializing Erivedge(R) for the treatment of advanced basal cell carcinoma. For more information, visit Curis's website at www.curis.com

https://c212.net/c/img/favicon.png?sn=NE00616&sd=2024-04-30

View original content to download multimedia:https://www.prnewswire.com/news-releases/curis-to-release-first-quarter-2024-financial-results-and-hold-conference-call-on-may-7-2024-302131015.html

SOURCE Curis, Inc.

https://rt.newswire.ca/rt.gif?NewsItemId=NE00616&Transmission_Id=202404300800PR_NEWS_USPR_____NE00616&DateId=20240430

COMTEX_451655221/1005/2024-04-30T08:01:44